Amniotic membrane-derived stem cells: immunomodulatory properties and potential clinical application
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Epithelial and mesenchymal cells isolated from the amniotic membrane (AM) possess stem cell characteristics, differentiation potential toward lineages of different germ layers, and immunomodulatory properties. While their expansion and differentiation potential have been well studied and characterized, knowledge about their immunomodulatory properties and the mechanisms involved is still incomplete. These mechanisms have been evaluated on various target cells of the innate and the adaptive system and in animal models of different inflammatory diseases. Some results have evidenced that the immunomodulatory effect of AM-derived cells is dependent on cell-cell contact, but many of them have demonstrated that these properties are mediated through the secretion of suppressive molecules. In this review, we present an update on the described immunomodulatory properties of the derived amniotic cells and some of the proposed involved mechanisms. Furthermore, we describe some assays in animal models of different inflammatory diseases which reveal the potential use of these cells to treat such diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101 · cited 2×
“It is likely that through the synergistic action of the chemokines and adhesion molecules, immune cells accumulate in close proximity to the MSCs, where the high concentration of secreted factors can suppress immune cells effector functions.(53,54) In response to immune cells, HAMSCs, as MSCs obtained from other sourc…”
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · cited 2×
“They neither express the programmed cell death receptor 1 (PD1) (an inhibitory receptor that is normally expressed on activated T and B cells), nor its two ligands: programmed death ligands 1 and 2 (PD-L1 and PD-L2).(15,16,23) These two are typically upregulated by stimulation with IFN-γ.”
Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956
Cited by
Modulators of the Balance between M1 and M2 Macrophages during Pregnancy
Zhang, Y.-H., He, M., Wang, Y., & Liao, A.-H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00120 · Cited by 292
Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes
Lebreton, F., Lavallard, V., Bellofatto, K., Bonnet, R., Wassmer, C. H., Perez, L., Kalandadze, V., Follenzi, A., Boulvain, M., Kerr-Conte, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12472-3 · Cited by 157
“Amniotic membranes were obtained from term healthy placentas of women undergoing elective cesarean section, under pre-Basec CCER protocol PB_2017-00101 (14-273), listed at https://www.”
MethodQiu, X., Liu, S., Zhang, H., Zhu, B., Su, Y., Zheng, C., Tian, R., Wang, M., Kuang, H., Zhao, X., et al. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0821-5 · Cited by 111
Coronado, R. E., Somaraki-Cormier, M., Ong, J. L., & Halff, G. A. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101471 · Cited by 20
Metadata
- Authors
- Insausti, C., Blanquer, M., García, A., Castellanos, G., & Moraleda, J. M.
- Venue
- Stem Cells and Cloning: Advances and Applications
- Publisher
- Informa UK Limited
- Published
- 2014-03
- Volume
- Volume 7
- Pages
- 53
- ISSN
- 1178-6957 (ISSN-L)
- OpenAlex
- W2102679822
- Cited by
- 139
- References
- 4
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.